Search

Your search keyword '"Geskin L"' showing total 174 results
Start Over Author "Geskin L"
174 results on '"Geskin L"'

10. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Author

Quaglino, P., Maule, M., Prince, H. M., Porcu, P., Horwitz, S., Duvic, M., Talpur, R., Vermeer, M., Bagot, M., Guitart, J., Papadavid, E., Sanches, J. A., Hodak, E., Sugaya, M., Berti, E., Ortiz-Romero, P., Pimpinelli, N., Servitje, O., Pileri, A., Zinzani, P. L., Estrach, T., Knobler, R., Stadler, R., Fierro, M. T., Alberti Violetti, S., Amitay-Laish, I., Antoniou, C., Astrua, C., Chaganti, S., Child, F., Combalia, A., Fabbro, S., Fava, P., Grandi, V., Jonak, C., Martinez-Escala, E., Kheterpal, M., Kim, E. J., McCormack, C., Miyagaki, T., Miyashiro, D., Morris, S., Muniesa, C., Nikolaou, V., Ognibene, G., Onida, F., Osella-Abate, S., Porkert, S., Postigo-Llorente, C., Ram-Wolff, C., Ribero, S., Rogers, K., Sanlorenzo, M., Stranzenbach, R., Spaccarelli, N., Stevens, A., Zugna, D., Rook, A. H., Geskin, L. J., Willemze, R., Whittaker, S., Hoppe, R., Scarisbrick, J., and Kim, Y.

Published
2017
Full Text
View/download PDF

11. Should we be imaging lymph nodes at initial diagnosis of early‐stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*

Author

Hodak, E., Sherman, S., Papadavid, E., Bagot, M., Querfeld, C., Quaglino, P., Prince, H.M., Ortiz-Romero, P.L., Stadler, R., Knobler, R., Guenova, E., Estrach, T., Patsatsi, A., Leshem, Y.A., Prague-Naveh, H., Berti, E., Alberti-Violetti, S., Cowan, R., Jonak, C., Nikolaou, V., Mitteldorf, C., Akilov, O., Geskin, L., Matin, R., Beylot-Barry, M., Vakeva, L., Sanches, J.A., Servitje, O., Weatherhead, S., Wobser, M., Yoo, J., Bayne, M., Bates, A., Dunnill, G., Marschalko, M., Buschots, A.M., Wehkamp, U., Evison, F., Hong, E., Amitay-Laish, I., Stranzenbach, R., Vermeer, M., Willemze, R., Kempf, W., Cerroni, L., Whittaker, S., Kim, Y.H., Scarisbrick, J.J., Cutaneous Lymphoma Int Consortium, HUS Inflammation Center, Clinicum, and Helsinki University Hospital Area

Subjects
medicine.medical_specialty, Skin Neoplasms, EUROPEAN-ORGANIZATION, SOCIETY, Physical examination, Dermatology, GUIDELINES, CLASSIFICATION, Cutaneous lymphoma, Cutaneous patch, 030207 dermatology & venereal diseases, 03 medical and health sciences, Mycosis Fungoides, 0302 clinical medicine, International Prognostic Index, Biopsy, SEZARY-SYNDROME, medicine, Humans, COMPUTED-TOMOGRAPHY, Prospective Studies, Stage (cooking), RESPONSE CRITERIA, Neoplasm Staging, Body surface area, Mycosis fungoides, medicine.diagnostic_test, business.industry, CONSORTIUM, Prognosis, medicine.disease, 3121 General medicine, internal medicine and other clinical medicine, SURVIVAL, Lymph Nodes, Radiology, business, TASK-FORCE
Abstract

Background Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. Objectives To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. Methods A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. Results PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (>= 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (>= 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. Conclusions Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.

Published
2020

15. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study

Author

Hodak, E. Sherman, S. Papadavid, E. Bagot, M. Querfeld, C. Quaglino, P. Prince, H. M. Ortiz-Romero, P. L. and Stadler, R. Knobler, R. Guenova, E. Estrach, T. and Patsatsi, A. Leshem, Y. A. Prague-Naveh, H. Berti, E. and Alberti-Violetti, S. Cowan, R. Jonak, C. Nikolaou, V and Mitteldorf, C. Akilov, O. Geskin, L. Matin, R. and Beylot-Barry, M. Vakeva, L. Sanches, J. A. Servitje, O. and Weatherhead, S. Wobser, M. Yoo, J. Bayne, M. Bates, A. and Dunnill, G. Marschalko, M. Buschots, A. M. Wehkamp, U. and Evison, F. Hong, E. Amitay-Laish, I Stranzenbach, R. and Vermeer, M. Willemze, R. Kempf, W. Cerroni, L. and Whittaker, S. Kim, Y. H. Scarisbrick, J. J. Cutaneous Lymphoma Int Consortium

Abstract

Background Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. Objectives To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. Methods A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. Results PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (>= 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (>= 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. Conclusions Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.

Published
2021

16. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data

Author

Horwitz, SM, Scarisbrick, JJ, Dummer, R, Whittaker, S, Duvic, M, Kim, YH, Quaglino, P, Zinzani, PL, Bechter, O, Eradat, H, Pinter-Brown, L, Akilov, OE, Geskin, L, Sanches, JA, Ortiz-Romero, PL, Weichenthal, M, Fisher, DC, Walewski, J, Trotman, J, Taylor, K, Dalle, S, Stadler, R, Lisano, J, Bunn, V, Little, M, Prince, HM, Horwitz, SM, Scarisbrick, JJ, Dummer, R, Whittaker, S, Duvic, M, Kim, YH, Quaglino, P, Zinzani, PL, Bechter, O, Eradat, H, Pinter-Brown, L, Akilov, OE, Geskin, L, Sanches, JA, Ortiz-Romero, PL, Weichenthal, M, Fisher, DC, Walewski, J, Trotman, J, Taylor, K, Dalle, S, Stadler, R, Lisano, J, Bunn, V, Little, M, and Prince, HM

Abstract

The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting ≥4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in CD30-expressing mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (C-ALCL). Cutaneous T-cell lymphomas often cause pruritus and pain; brentuximab vedotin improved skin symptom burden with no negative effects on quality of life. We report final data from ALCANZA (median follow-up, 45.9 months). Adults with previously treated CD30-expressing MF/C-ALCL were randomly assigned to brentuximab vedotin (n = 64) or physician's choice (n = 64). Final data demonstrated improved responses per independent review facility with brentuximab vedotin vs physician's choice: ORR4; 54.7% vs 12.5% (P < .001); complete response, 17.2% vs 1.6% (P = .002). Median PFS with brentuximab vedotin vs physician's choice was 16.7 months vs 3.5 months (P < .001). Median time to the next treatment was significantly longer with brentuximab vedotin than with physician's choice (14.2 vs 5.6 months; hazard ratio, 0.27; 95% confidence interval, 0.17-0.42; P < .001). Of 44 patients in the brentuximab vedotin arm who experienced any-grade peripheral neuropathy, (grade 3, n = 6; grade 4, n = 0), 86% (38 of 44) had complete resolution (26 of 44) or improvement to grades 1 and 2 (12 of 44). Peripheral neuropathy was ongoing in 18 patients (all grades 1-2). These final analyses confirm improved, clinically meaningful, durable responses and longer PFS with brentuximab vedotin vs physician's choice in CD30-expressing MF or C-ALCL. This trial was registered at https://www.clinicaltrials.gov as #NCT01578499.

Published
2021

19. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study

Author

Hodak, E, Sherman, S, Papadavid, E, Bagot, M, Querfeld, C, Quaglino, P, Prince, HM, Ortiz-Romero, PL, Stadler, R, Knobler, R, Guenova, E, Estrach, T, Patsatsi, A, Leshem, YA, Prague-Naveh, H, Berti, E, Alberti-Violetti, S, Cowan, R, Jonak, C, Nikolaou, V, Mitteldorf, C, Akilov, O, Geskin, L, Matin, R, Beylot-Barry, M, Vakeva, L, Sanches, JA, Servitje, O, Weatherhead, S, Wobser, M, Yoo, J, Bayne, M, Bates, A, Dunnill, G, Marschalko, M, Buschots, AM, Wehkamp, U, Evison, F, Hong, E, Amitay-Laish, I, Stranzenbach, R, Vermeer, M, Willemze, R, Kempf, W, Cerroni, L, Whittaker, S, Kim, YH, Scarisbrick, JJ, Hodak, E, Sherman, S, Papadavid, E, Bagot, M, Querfeld, C, Quaglino, P, Prince, HM, Ortiz-Romero, PL, Stadler, R, Knobler, R, Guenova, E, Estrach, T, Patsatsi, A, Leshem, YA, Prague-Naveh, H, Berti, E, Alberti-Violetti, S, Cowan, R, Jonak, C, Nikolaou, V, Mitteldorf, C, Akilov, O, Geskin, L, Matin, R, Beylot-Barry, M, Vakeva, L, Sanches, JA, Servitje, O, Weatherhead, S, Wobser, M, Yoo, J, Bayne, M, Bates, A, Dunnill, G, Marschalko, M, Buschots, AM, Wehkamp, U, Evison, F, Hong, E, Amitay-Laish, I, Stranzenbach, R, Vermeer, M, Willemze, R, Kempf, W, Cerroni, L, Whittaker, S, Kim, YH, and Scarisbrick, JJ

Abstract

BACKGROUND: Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. OBJECTIVES: To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. METHODS: A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. RESULTS: PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (≥ 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (≥ 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. CONCLUSIONS: Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients w

Published
2020

26. The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-Life Clinical Data

Author

Amitay-Laish, I, primary, Guenova, E, additional, Ortiz-Romero, P, additional, Vico-Alonso, C, additional, Rozati, S, additional, Geskin, L, additional, Nikolaou, V, additional, Papadavid, E, additional, Barzilai, A, additional, Pavlovsky, L, additional, Didkovsky, E, additional, Naveh, H, additional, Akilov, O, additional, and Hodak, E, additional

Published
2020
Full Text
View/download PDF

30. Corrigendum: Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (Annals of Oncology (2017) 28 (2517-2525) DOI: 10.1093/annonc/mdx352)

Author

Quaglino, P., Maule, M., Prince, H. M., Porcu, P., Horwitz, S., Duvic, M., Talpur, R., Vermeer, M., Bagot, M., Guitart, J., Papadavid, E., Sanches, J. A., Hodak, E., Sugaya, M., Berti, E., Ortiz-Romero, P., Pimpinelli, N., Servitje, O., Pileri, A., Zinzani, P. L., Estrach, T., Knobler, R., Stadler, R., Fierro, M. T., Alberti Violetti, S., Amitay-Laish, I., Antoniou, C., Astrua, C., Chaganti, S., Child, F., Combalia, A., Fabbro, S., Fava, P., Grandi, V., Jonak, C., Martinez-Escala, E., Kheterpal, M., Kim, E. J., Mccormack, C., Miyagaki, T., Miyashiro, D., Morris, S., Muniesa, C., Nikolaou, V., Ognibene, G., Onida, F., Osella-Abate, S., Porkert, S., Postigo-Llorente, C., Ram-Wolff, C., Ribero, S., Rogers, K., Sanlorenzo, M., Stranzenbach, R., Spaccarelli, N., Stevens, A., Zugna, D., Rook, A. H., Geskin, L. J., Willemze, R., Whittaker, S., Hoppe, R., Scarisbrick, J., and Kim, Y.

Published
2019

33. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, Willemze, R, Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, and Willemze, R

Abstract

BACKGROUND: Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES: To develop a prognostic index for MF. METHODS: Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS: In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS: This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.

Published
2019

37. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL)

Author

Horwitz, S.M., primary, Scarisbrick, J., additional, Prince, H.M., additional, Whittaker, S., additional, Duvic, M., additional, Kim, Y.H., additional, Quaglino, P., additional, Zinzani, P.L., additional, Bechter, O., additional, Eradat, H., additional, Pinter-Brown, L., additional, Akilov, O., additional, Geskin, L., additional, Sanches, J., additional, Ortiz-Romero, P., additional, Lisano, J., additional, Brown, L., additional, Palanca-Wessels, M.C., additional, Gautam, A., additional, Bunn, V., additional, Little, M., additional, and Dummer, R., additional

Published
2019
Full Text
View/download PDF

38. CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30-POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202)

Author

Sawas, A., primary, Chen, P., additional, Vlad, G., additional, Lipschitz, M., additional, Abdul-Hay, M., additional, Lue, J., additional, Deng, C., additional, Amengual, J.E., additional, Marchi, E., additional, Shulman, J., additional, Elgedawe, H., additional, Shong, M.V., additional, Khan, K., additional, Geskin, L., additional, Rodig, S.J., additional, and O'Connor, O., additional

Published
2019
Full Text
View/download PDF

39. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, J.J., primary, Quaglino, P., additional, Prince, H.M., additional, Papadavid, E., additional, Hodak, E., additional, Bagot, M., additional, Servitje, O., additional, Berti, E., additional, Ortiz‐Romero, P., additional, Stadler, R., additional, Patsatsi, A., additional, Knobler, R., additional, Guenova, E., additional, Child, F., additional, Whittaker, S., additional, Nikolaou, V., additional, Tomasini, C., additional, Amitay, I., additional, Prag Naveh, H., additional, Ram‐Wolff, C., additional, Battistella, M, additional, Alberti‐Violetti, S., additional, Stranzenbach, R., additional, Gargallo, V., additional, Muniesa, C., additional, Koletsa, T., additional, Jonak, C., additional, Porkert, S., additional, Mitteldorf, C., additional, Estrach, T., additional, Combalia, A., additional, Marschalko, M., additional, Csomor, J., additional, Szepesi, A., additional, Cozzio, A., additional, Dummer, R., additional, Pimpinelli, N., additional, Grandi, V., additional, Beylot‐Barry, M., additional, Pham‐Ledard, A., additional, Wobser, M., additional, Geissinger, E., additional, Wehkamp, U., additional, Weichenthal, M., additional, Cowan, R., additional, Parry, E., additional, Harris, J., additional, Wachsmuth, R., additional, Turner, D., additional, Bates, A., additional, Healy, E., additional, Trautinger, F., additional, Latzka, J., additional, Yoo, J., additional, Vydianath, B., additional, Amel‐Kashipaz, R., additional, Marinos, L., additional, Oikonomidi, A., additional, Stratigos, A., additional, Vignon‐Pennamen, M.‐D., additional, Battistella, M., additional, Climent, F., additional, Gonzalez‐Barca, E., additional, Georgiou, E., additional, Senetta, R., additional, Zinzani, P., additional, Vakeva, L., additional, Ranki, A., additional, Busschots, A.‐M., additional, Hauben, E., additional, Bervoets, A., additional, Woei‐A‐Jin, F.J.S.H., additional, Matin, R., additional, Collins, G., additional, Weatherhead, S., additional, Frew, J., additional, Bayne, M., additional, Dunnill, G., additional, McKay, P., additional, Arumainathan, A., additional, Azurdia, R., additional, Benstead, K., additional, Twigger, R., additional, Rieger, K., additional, Brown, R., additional, Sanches, J.A., additional, Miyashiro, D., additional, Akilov, O., additional, McCann, S., additional, Sahi, H., additional, Damasco, F.M., additional, Querfeld, C., additional, Folkes, A., additional, Bur, C., additional, Klemke, C.‐D., additional, Enz, P., additional, Pujol, R., additional, Quint, K., additional, Geskin, L., additional, Hong, E., additional, Evison, F., additional, Vermeer, M., additional, Cerroni, L., additional, Kempf, W., additional, Kim, Y., additional, and Willemze, R., additional

Published
2018
Full Text
View/download PDF

45. PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY

Author

Prince, H.M., primary, Dummer, R., additional, Whittaker, S., additional, Horwitz, S., additional, Duvic, M., additional, Scarisbrick, J., additional, Quaglino, P., additional, Zinzani, P.L., additional, Wolter, P., additional, Sanches, J., additional, Ortiz-Romero, P., additional, Akilov, O., additional, Geskin, L., additional, Huen, A., additional, Wang, Y., additional, Palanca-Wessels, M.C., additional, Richhariya, A., additional, Feliciano, J., additional, Zhu, Y., additional, Lin, H., additional, Liu, Y., additional, Little, M., additional, Zagadailov, E., additional, Dalal, M., additional, and Kim, Y.H., additional

Published
2017
Full Text
View/download PDF

49. LYMPH NODE AND SKIN SCORING GROWTH KINETICS PREDICT OUTCOMES IN CUTANEOUS T‐CELL LYMPHOMA: AN INTERIM ANALYSIS.

Author

Fahmy, L. M., Yang, H. R., Zhou, M., Beylergil, V., Schreidah, C. M., Kwinta, B. D., Schwartz, L. H., Fojo, A. T., Bates, S. E., and Geskin, L. J.

Subjects
CUTANEOUS T-cell lymphoma, LYMPH nodes
Abstract

LYMPH NODE AND SKIN SCORING GROWTH KINETICS PREDICT OUTCOMES IN CUTANEOUS T-CELL LYMPHOMA: AN INTERIM ANALYSIS Our interim analysis demonstrates that skin scoring and lymph node growth kinetics predict survival in CTCL. In cutaneous T-cell lymphoma (CTCL), skin scoring and lymph node (LN) assessment are essential for scoring disease response in both clinical practice and in trials. [Extracted from the article]

Published
2023
Full Text
View/download PDF

50. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Author

Olsen, Ea, Whittaker, S, Kim, Yh, Duvic, M, Prince, Hm, Lessin, Sr, Wood, Gs, Willemze, R, Demierre, Mf, Pimpinelli, Nicola, Bernengo, Mg, Ortiz Romero PL, Bagot, M, Estrach, T, Guitart, J, Knobler, R, Sanches, Ja, Iwatsuki, K, Sugaya, M, Dummer, R, Pittelkow, M, Hoppe, R, Parker, S, Geskin, L, Pinter Brown, L, Girardi, M, Burg, G, Ranki, A, Vermeer, M, Horwitz, S, Heald, P, Rosen, S, Cerroni, L, Dreno, B, Vonderheid, Ec, International Society for Cutaneous Lymphomas, United States Cutaneous Lymphoma Consortium, Cutaneous Lymphoma Task Force of the European Organisation for Research, and Treatment of Cancer

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results